Loading
A phase 3 trial of Epcoritamab, Prednisone, Rituximab in follicular lymphoma, run by Genmab, active and no longer recruiting.
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma is a phase 3 interventional study registered as NCT06191744 by Genmab, with 1095 participants enrolled, started 2024-02-05 and due to reach its primary completion in 2037-11. Interventions recorded: Epcoritamab, Prednisone, Rituximab, Lenalidomide, Doxorubicin. Conditions listed: Follicular Lymphoma (FL). No results are recorded here; the registry entry is the source.
Shares Epcoritamab, Genmab, Lenalidomide, PROTACs & molecular glues (targeted protein degradation).
Shares Epcoritamab, Genmab, Prednisone, Vincristine.
Shares Epcoritamab, Genmab, Prednisone, Vincristine.
Shares Epcoritamab, Genmab, Lenalidomide, PROTACs & molecular glues (targeted protein degradation).
Shares Lenalidomide, PROTACs & molecular glues (targeted protein degradation), Vincristine, Rituximab.
Shares Epcoritamab, Genmab, Lenalidomide, Prednisone.
Shares Genmab, Lenalidomide, Prednisone, Vincristine.
Shares Prednisone, Vincristine, Rituximab, T-cell engagers (bispecific).